In order to evaluate the relationship between endorphin system and dopamine system in chronic schizophrenia, we have examined ^-endorphin like substance level in the plasma and CSF of 40 chronic schizophrenia (male 20 and female 20, mean age 30.1± 14. 6) w ith ^-endorphin radioimmunoassay kit supplied by New England Nuclear. There were no significant differences in plasma and in CSF between mean /3-endorphin levels of the schizophrenia after 17 days antipsychotic drugs w ith drawal period (plasma 116. 7±15. Opg/ml and 94.1 ±9. Opg/ml) and controls (plasma 63. 2 ±11. 9pg/ml and 64. 4 ± 12. Opg/ml). After 17 days antipsychotic drugs w ithdraw al period, the schizophrenic patients were randomly subdivided into haloperid이 group (male 10 and female 10) and low dose (0. 6mg/day) bromocriptine group (male 10 and female 10). The mean levels of jS-endorphin were significantly reduced after 21 days haloperidol treatment compared with after 17 days antipsychotic drugs w ithdraw al period in plasma (before treatment, 120. ±42. lpg /ml and after treatment, 48. 8±16. 3pg/ml, p < 0 . 05) but not in CSF (before treatment, 74.8±15.8pg/ml and after treatment 30.2±5. lp g /m l). However after 21 days low dose (0. 6mg/day) bromocriptine treatment, there were significant reduction of mean levels of /3-endorphin both in plasma (before treatment, 122. 7±26. lp g /m l and after treatment, 46. 6 ±10. 5pg/ml, p < 0 . 001) and in C SF (before treat-ment, 99.8 ±16. 3pg/ml and after treatment, 29. 3 ±6. lp g /m l p < 0 . 01). No relationships between plasma and CSF b-endorphin levels and BPRS total scores of AIMS highest scores were found in the haloperi- dol group and the low dose (0. 6mg/day) bromoc-riptine group.
서 론
방 법
결 과
고 찰
요 약
REFERENCES